Zimmer/TSL 6-Month Permacol Trial To Support 2004 Launch
This article was originally published in The Gray Sheet
Executive Summary
Zimmer expects to launch Tissue Science Laboratories' Permacol in the U.S. in the second half of next year for shoulder rotator cuff repair following a six-month trial to support marketing efforts
You may also be interested in...
Zimmer/Centerpulse Merger Would Build Minimally-Invasive Surgery Portfolio
Centerpulse's allogenic bone concentrate (ABC) would give Zimmer a spine fusion product to compete directly with Medtronic Sofamor Danek's InFuse bone graft/LT-CAGE lumbar tapered fusion device
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.